Revolution Medicines, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $11.6M | $35.4M | $29.4M |
| Operating income | -$1.2B | -$689.5M | -$487.2M | -$258.3M | -$188.0M |
| Operating expenses | $1.2B | $689.5M | $498.8M | $293.7M | $217.4M |
| Cash from operations | -$897.7M | -$557.4M | -$350.6M | -$224.4M | -$147.2M |
| Capital expenditure | $16.0M | $10.3M | $7.7M | $10.8M | $6.5M |
| Free cash flow | -$913.7M | -$567.7M | -$358.3M | -$235.2M | -$153.7M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $2.4B | $2.6B | $2.1B | $811.9M | $738.0M |
| Total liabilities | $723.2M | $293.1M | $235.5M | $126.7M | $135.4M |
Shares outstanding 212.6M · Free float 92.7%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.